Clinical trial NCT04616391 - References

Diabetes Mellitus, Type 1 — AHCL System Initiation in T1D Patients naïve to Technology

Citation(s)

•   Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group
  Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes U
•   Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR
  Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA. 2016 Oct 4;316(13):1407-1408. doi: 10.1001/jama.2016.11708.
•   Cordero TL, Garg SK, Brazg R, Bailey TS, Shin J, Lee SW, Kaufman FR
  The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed(™) 670G Hybrid Closed-Loop System. Diabetes Technol Ther. 2017 Dec;19(12):7
•   Forlenza GP, Messer LH, Berget C, Wadwa RP, Driscoll KA
  Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field. Curr Diab Rep. 2018 Sep 26;18(11):114. do
•   Petrovski G, Al Khalaf F, Campbell J, Fisher H, Umer F, Hussain K
  10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol. 2020 Jun;57(6):681-687. do

Transition of Patients With T1D From Multiple Daily Injection (MDI) and Self-Monitoring of Blood Glucose (SMBG) Directly to MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) System :Impact on Glucose Control and Quality of Life Measures

Details for clinical trial NCT04616391